Most medical device companies monitor their own adverse events because they have to. The FDA's mandatory reporting requirements under 21 CFR Part 803 make it non-negotiable. But monitoring competitor devices? That is almost always optional — and almost always undervalued.
Systematic competitor device monitoring is one of the highest-leverage activities a regulatory or quality team can perform. It provides early warning of class-wide issues, market intelligence that informs product strategy, and benchmarking data that strengthens your own regulatory submissions. Yet the majority of device companies either skip it entirely or do it sporadically, usually triggered by a field safety notice that happens to cross someone's desk.
This article makes the case for building a systematic competitor monitoring program and explains how to do it.
Why Competitor Monitoring Matters
There are three distinct categories of value that competitor monitoring delivers:
Early Warning of Class-Wide Issues
When a competitor device experiences a pattern of adverse events related to a shared technology, material, or design approach, that pattern is potentially relevant to your device. If you share a common predicate device, use the same biocompatible material, or employ a similar mechanism of action, a safety signal in a competitor product is an early warning for your own portfolio.
Consider a practical example: two companies market pedicle screw systems using the same titanium alloy from the same material supplier. If one company sees an increase in fracture-related adverse events, the other company should know about it — ideally before they see the same pattern in their own data.
This kind of cross-manufacturer signal detection is not theoretical. The FDA's own signal detection activities look across all devices within a product code precisely because class-wide issues are common in medical devices.
Market Intelligence
Adverse event patterns tell you things about competitor products that marketing materials and 510(k) summaries never will. A competitor device with a high rate of use-error-related events may have usability problems. A pattern of insertion-related complications may indicate a design issue. A cluster of events related to labeling or instructions for use may indicate gaps in user training.
This is not about schadenfreude — it is about understanding the competitive landscape with data rather than assumptions. If your competitor's device has a specific failure mode that your design avoids, that is a legitimate differentiator worth highlighting in sales and marketing conversations (appropriately and factually, of course).
Conversely, if your competitor is seeing issues that your design is also susceptible to, you have an opportunity to take proactive corrective action before the issue manifests in your own product.
Regulatory Benchmarking
Regulatory submissions — whether 510(k) premarket notifications, PMA applications, or EU MDR clinical evaluation reports — benefit from comparative safety data. Demonstrating that your device's adverse event profile is comparable to or better than the predicate or equivalent device strengthens your regulatory narrative.
For clinical evaluation reports under EU MDR, equivalence claims require a thorough analysis of the equivalent device's safety and performance data. Adverse event data from MAUDE is a critical input to this analysis. Having a systematic, well-documented competitor monitoring program provides the raw data for these comparisons.
Setting Up a Systematic Monitoring Program
A competitor monitoring program does not need to be complicated, but it does need to be systematic. Here are the essential components:
Define Your Competitive Scope
Start by identifying which competitor devices to monitor. The most important criterion is shared product code — devices classified under the same FDA product code as your device are, by definition, in the same device category and are the most relevant comparators.
Beyond your immediate product code, consider:
- Predicate devices listed in your 510(k) submissions
- Equivalent devices claimed in your EU MDR clinical evaluation reports
- Adjacent product codes that share key technology or materials with your device
- Market leaders in your therapeutic area, regardless of product code similarity
For most companies, this produces a monitoring list of 5-20 competitor devices. More than that, and you risk drowning in data without proportional benefit.
Establish Your Monitoring Cadence
Weekly monitoring strikes the right balance between timeliness and workload for most device types. The FDA updates the openFDA database regularly, and weekly queries ensure you catch new reports within a reasonable timeframe.
For higher-risk devices (Class III, life-sustaining devices) or during periods of heightened concern (after a competitor recall, for example), you may want to increase to twice-weekly monitoring.
Decide What You Are Looking For
Not all competitor adverse events are equally relevant. Focus your analysis on:
New failure modes that have not previously been associated with this device type. These represent potential emerging risks that may affect your product as well.
Increasing frequency of a known failure mode. A stable low-level rate of a known complication is expected; a sudden increase demands attention.
Severe outcomes associated with events that are typically lower-severity. If a failure mode that usually results in device replacement is now causing hospitalizations, that is a significant change.
Recalls and field safety corrective actions triggered by adverse event patterns. These are publicly available through the FDA's recall database and the FSCA database in Europe, and they represent the most serious validation of a safety signal.
Labeling-related events that suggest user comprehension issues common to the device category.
Document Your Methodology
This is critical and often overlooked. Your competitor monitoring program should be described in your post-market surveillance plan with sufficient detail that an auditor or notified body can assess its adequacy. Document:
- Which competitors and product codes you monitor
- How frequently you search
- What data sources you use
- How you analyze and escalate findings
- How findings feed into your risk management process
This documentation transforms competitor monitoring from an ad hoc activity into a controlled, auditable process that demonstrates regulatory diligence.
What to Do With the Data
Collecting competitor adverse event data is only valuable if it feeds into your decision-making processes:
Risk management: Update your risk analysis (ISO 14971) when competitor data reveals failure modes or hazardous situations not previously considered. Even if the failure mode is specific to the competitor's design, the hazardous situation may be relevant to your device.
Design inputs: If competitor data reveals a design-related issue that your next-generation product could address, that becomes a design input with real-world evidence supporting its priority.
Clinical evaluation: For EU MDR clinical evaluation reports, competitor adverse event data provides the real-world safety data needed for equivalence analysis or state-of-the-art comparison.
Regulatory submissions: Comparative safety data strengthens 510(k) submissions and PMA annual reports. Showing that your device's adverse event profile is favorable compared to the predicate is a powerful data point.
Customer conversations: Sales and clinical teams benefit from understanding the competitive safety landscape. Factual, data-driven comparisons (never sensationalized) can differentiate your product in evaluation processes.
Why Manual Monitoring Fails
The reason most companies do not monitor competitors systematically is simple: it is a lot of work to do manually. Every additional product code you monitor multiplies the number of reports you need to read, classify, and track. When the team is already struggling to keep up with their own device's adverse events, adding competitor monitoring to the manual workload is rarely prioritized.
This is where automation changes the equation. A platform like DeviceWatch allows you to add competitor product codes alongside your own monitored devices. The same automated pipeline — openFDA data ingestion, AI-powered narrative analysis, trend detection, and human review — applies to competitor devices as well. The marginal cost of monitoring an additional competitor is near zero.
Instead of competitor monitoring being a resource constraint that your team works around, it becomes a standard capability built into your surveillance program. The AI handles the data processing; your team focuses on interpreting the findings and making strategic decisions.
The Competitive Advantage of Knowing More
In a regulated industry, information asymmetry matters. The company that understands the full safety landscape of its device category — not just its own events, but the industry-wide picture — makes better decisions about design, risk management, and regulatory strategy.
Competitor monitoring is not espionage. The data is public. The FDA publishes it precisely because transparency in device safety benefits patients and the industry. The competitive advantage comes not from access to the data — everyone has that — but from the discipline to systematically collect, analyze, and act on it.
Build the system. Monitor the field. Let the data sharpen your strategy.